Concepedia

Sundar Neelakantan

SN

9

Publications

988

Citations

9

H-Index

2003

Active since

Affiliations

University of Kentucky(Current)

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

University of Rochester

Dana-Farber Cancer Institute

Sundar Neelakantan is an author at University of Kentucky specializing in drug discovery, pharmacology, and medicine.

Top concepts

Publications per year

2003–2010

9

Publications

9

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Mónica L. Guzmán, Randall M. Rossi, Sundar Neelakantan et al. · Blood · 2007 · 407 citations · Full text

Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)

Sundar Neelakantan, Shama Nasim, Mónica L. Guzmán et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 188 citations

, , +10

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Saman Hewamana, Suhair Alghazal, Thet Thet Lin et al. · Blood · 2008 · 154 citations · Full text

A water soluble parthenolide analog suppresses <i>in vivo</i> tumor growth of two tobacco‐associated cancers, lung and bladder cancer, by targeting NF‐κB and generating reactive oxygen species

Rajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah et al. · International Journal of Cancer · 2010 · 74 citations · Full text

A water‐soluble parthenolide analogue suppresses in vivo <i>prostate cancer</i> growth by targeting NFκB and generating reactive oxygen species

Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng et al. · The Prostate · 2010 · 66 citations

Rows per page

1–5 of 9